Selected work
Client engagements are confidential. Here is what we were asked, what we built, and what it found.
Which late-stage assets could we in-license that fit our franchise and launch before 2028?
ResultThe top targets moved on to business cases, and the client came back for a second engagement.
Is there a case for a next-generation drug in our core franchise, and in which indication first?
ResultThree lead indications and a shortlist of licensable assets across industry and academia.
Where is the ADC class selling, where are new assets coming from, and what are deals actually paying?
Finding65% of active clinical ADCs now originate in China, and China→West licenses pay a median of about 5% of headline value upfront.
What at this congress matters to our assets, and who on the team should be in which room?
DeliversA priority report with implications, built on an annotated abstract library; a session planning grid; and a pre-congress executive deck.
Which directors and specialist funds connect the companies we compete with, or want to partner with?
OriginThe investor map began as a project for a hedge-fund client. The same approach maps KOL networks.
Our thinking
CI is a function. Competitive readiness is a culture.
Why client context turns generic AI output into decision-grade CI.
Our approach, how our analysis engine works, our services, and selected work.